Cargando…

Lipid profile after omega-3 supplementation in neonates with intrauterine growth retardation: a randomized controlled trial

BACKGROUND: Neonates with intrauterine growth restriction (IUGR) have a high lipid profile that predisposes them to cardiovascular disease later in life. We aimed to evaluate the effect of omega 3 supplementation on serum leptin level, lipid profile, and growth in neonates with IUGR. METHODS: This c...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsheikh, Mai, El Amrousy, Doaa, El-Mahdy, Heba, Dawoud, Heba, Harkan, Ahmed, El-Barky, Amany
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589086/
https://www.ncbi.nlm.nih.gov/pubmed/37202530
http://dx.doi.org/10.1038/s41390-023-02632-z
_version_ 1785123717492244480
author Elsheikh, Mai
El Amrousy, Doaa
El-Mahdy, Heba
Dawoud, Heba
Harkan, Ahmed
El-Barky, Amany
author_facet Elsheikh, Mai
El Amrousy, Doaa
El-Mahdy, Heba
Dawoud, Heba
Harkan, Ahmed
El-Barky, Amany
author_sort Elsheikh, Mai
collection PubMed
description BACKGROUND: Neonates with intrauterine growth restriction (IUGR) have a high lipid profile that predisposes them to cardiovascular disease later in life. We aimed to evaluate the effect of omega 3 supplementation on serum leptin level, lipid profile, and growth in neonates with IUGR. METHODS: This clinical trial was conducted on 70 full-term neonates with IUGR. Neonates were randomly divided into two equal groups; the treatment group: received omega 3 supplement (40 mg/kg/day) for 2 weeks after the establishment of full feeding, and the control group, who were followed up to full feeding without any supplementation. Serum leptin level, total cholesterol (TC), high-density lipoprotein (HDL), triglycerides (TG), low-density lipoprotein (LDL), and anthropometric measurement were evaluated at admission and after 2 weeks of omega 3 supplementation in both groups. RESULTS: After treatment, HDL significantly increased, unlike TC, TG, LDL, LDL, and serum leptin levels, which significantly decreased in the treatment group compared to the control group after treatment. Interestingly, weight, length, and ponderal index greatly increased in omega 3-treated neonates compared to the control group. CONCLUSION: Omega 3 supplementations lowered serum leptin level, TG, TC, LDL, and VLDL but increased HDL and growth in neonates with IUGR. CLINICAL TRIAL REGISTRATION: The study was registered at clinicaltrials.gov (NCT05242107). IMPACT: Neonates with intrauterine growth retardation (IUGR) were reported to have a high lipid profile that predisposes them to cardiovascular disease later in life. Leptin is a hormone that adjusts dietary intake and body mass and has a significant role in fetal development. Omega 3 is known to be essential for neonatal growth and brain development. We aimed to evaluate the effect of omega 3 supplementation on serum leptin level, lipid profile, and growth in neonates with IUGR. We found that omega 3 supplementations lowered serum leptin level and serum lipid profile but increased high density lipoprotein and growth in neonates with IUGR.
format Online
Article
Text
id pubmed-10589086
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-105890862023-10-22 Lipid profile after omega-3 supplementation in neonates with intrauterine growth retardation: a randomized controlled trial Elsheikh, Mai El Amrousy, Doaa El-Mahdy, Heba Dawoud, Heba Harkan, Ahmed El-Barky, Amany Pediatr Res Clinical Research Article BACKGROUND: Neonates with intrauterine growth restriction (IUGR) have a high lipid profile that predisposes them to cardiovascular disease later in life. We aimed to evaluate the effect of omega 3 supplementation on serum leptin level, lipid profile, and growth in neonates with IUGR. METHODS: This clinical trial was conducted on 70 full-term neonates with IUGR. Neonates were randomly divided into two equal groups; the treatment group: received omega 3 supplement (40 mg/kg/day) for 2 weeks after the establishment of full feeding, and the control group, who were followed up to full feeding without any supplementation. Serum leptin level, total cholesterol (TC), high-density lipoprotein (HDL), triglycerides (TG), low-density lipoprotein (LDL), and anthropometric measurement were evaluated at admission and after 2 weeks of omega 3 supplementation in both groups. RESULTS: After treatment, HDL significantly increased, unlike TC, TG, LDL, LDL, and serum leptin levels, which significantly decreased in the treatment group compared to the control group after treatment. Interestingly, weight, length, and ponderal index greatly increased in omega 3-treated neonates compared to the control group. CONCLUSION: Omega 3 supplementations lowered serum leptin level, TG, TC, LDL, and VLDL but increased HDL and growth in neonates with IUGR. CLINICAL TRIAL REGISTRATION: The study was registered at clinicaltrials.gov (NCT05242107). IMPACT: Neonates with intrauterine growth retardation (IUGR) were reported to have a high lipid profile that predisposes them to cardiovascular disease later in life. Leptin is a hormone that adjusts dietary intake and body mass and has a significant role in fetal development. Omega 3 is known to be essential for neonatal growth and brain development. We aimed to evaluate the effect of omega 3 supplementation on serum leptin level, lipid profile, and growth in neonates with IUGR. We found that omega 3 supplementations lowered serum leptin level and serum lipid profile but increased high density lipoprotein and growth in neonates with IUGR. Nature Publishing Group US 2023-05-18 2023 /pmc/articles/PMC10589086/ /pubmed/37202530 http://dx.doi.org/10.1038/s41390-023-02632-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Research Article
Elsheikh, Mai
El Amrousy, Doaa
El-Mahdy, Heba
Dawoud, Heba
Harkan, Ahmed
El-Barky, Amany
Lipid profile after omega-3 supplementation in neonates with intrauterine growth retardation: a randomized controlled trial
title Lipid profile after omega-3 supplementation in neonates with intrauterine growth retardation: a randomized controlled trial
title_full Lipid profile after omega-3 supplementation in neonates with intrauterine growth retardation: a randomized controlled trial
title_fullStr Lipid profile after omega-3 supplementation in neonates with intrauterine growth retardation: a randomized controlled trial
title_full_unstemmed Lipid profile after omega-3 supplementation in neonates with intrauterine growth retardation: a randomized controlled trial
title_short Lipid profile after omega-3 supplementation in neonates with intrauterine growth retardation: a randomized controlled trial
title_sort lipid profile after omega-3 supplementation in neonates with intrauterine growth retardation: a randomized controlled trial
topic Clinical Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589086/
https://www.ncbi.nlm.nih.gov/pubmed/37202530
http://dx.doi.org/10.1038/s41390-023-02632-z
work_keys_str_mv AT elsheikhmai lipidprofileafteromega3supplementationinneonateswithintrauterinegrowthretardationarandomizedcontrolledtrial
AT elamrousydoaa lipidprofileafteromega3supplementationinneonateswithintrauterinegrowthretardationarandomizedcontrolledtrial
AT elmahdyheba lipidprofileafteromega3supplementationinneonateswithintrauterinegrowthretardationarandomizedcontrolledtrial
AT dawoudheba lipidprofileafteromega3supplementationinneonateswithintrauterinegrowthretardationarandomizedcontrolledtrial
AT harkanahmed lipidprofileafteromega3supplementationinneonateswithintrauterinegrowthretardationarandomizedcontrolledtrial
AT elbarkyamany lipidprofileafteromega3supplementationinneonateswithintrauterinegrowthretardationarandomizedcontrolledtrial